TME Pharma NV
ALTME
Company Profile
Business description
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).
Contact
Max-Dohrn-Street 8-10
Berlin10589
DEUT: +49 30166370820
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Competition restrains long-term margins.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.30 | 31.20 | 0.35% |
| CAC 40 | 8,044.51 | 68.39 | 0.86% |
| DAX 40 | 24,375.59 | 384.32 | 1.60% |
| Dow JONES (US) | 49,264.79 | 322.89 | 0.66% |
| FTSE 100 | 10,202.10 | 161.83 | -1.56% |
| HKSE | 25,898.61 | 197.27 | -0.76% |
| NASDAQ | 25,314.89 | 247.09 | 0.99% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,035.70 | 61.98 | -0.47% |
| S&P 500 | 7,259.18 | 58.43 | 0.81% |
| S&P/ASX 200 | 8,680.50 | 38.80 | 0.45% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |